Email address and contacts
PERCIVIA is a venture formed by Crucell N.V. and Royal DSM N.V., to develop recombinant therapeutic proteins using the PER.C6® human cell line, with a focus on biosimilar monoclonal antibodies globally. Additionally, PERCIVIA out-licenses the PER.C6® cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology to licensees. PERCIVIA’s unique advantage lies in the core technologies of PER.C6®, the company’s high yield proprietary human cell line, which enables SCALE™, a market-optimized manufacturing process, allowing for rapid facility set up with an “In Market, For Market”™ manufacturing solution.
6
United States
